These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37309116)

  • 1. Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea.
    Lee YK; Kwon Y; Heo Y; Kim EK; Kim SY; Cho H; Kim S; Ko M; Lim D; Seo SY; Cho E
    Clin Exp Pediatr; 2023 Oct; 66(10):415-423. PubMed ID: 37309116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.
    Ko M; Kim S; Choi SK; Shin SH; Lee YK; Kwon Y
    Osong Public Health Res Perspect; 2024 Aug; 15(4):364-374. PubMed ID: 38988090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea.
    Kim S; Hwang I; Ko M; Kwon Y; Lee YK
    Osong Public Health Res Perspect; 2022 Jun; 13(3):230-237. PubMed ID: 35820672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021.
    Oh HK; Kim EK; Hwang I; Kim TE; Lee YK; Lee E; Lee YK
    Osong Public Health Res Perspect; 2021 Aug; 12(4):264-268. PubMed ID: 34465075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea.
    Kwon Y; Hwang I; Ko M; Kim H; Kim S; Seo SY; Cho E; Lee YK
    Epidemiol Health; 2023; 45():e2023006. PubMed ID: 37183320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.
    Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y
    Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021.
    Hwang I; Park K; Kim TE; Kwon Y; Lee YK
    Osong Public Health Res Perspect; 2021 Dec; 12(6):396-402. PubMed ID: 34965689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273.
    Urdaneta V; Esposito DB; Dharia P; Moraga MS; Anteyi K; Oduyebo-Omotosho T; Rossi M; Burton P; Vega JM; Dawson R; Straus W
    Open Forum Infect Dis; 2024 Mar; 11(3):ofae067. PubMed ID: 38500575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    Takuva S; Takalani A; Seocharan I; Yende-Zuma N; Reddy T; Engelbrecht I; Faesen M; Khuto K; Whyte C; Bailey V; Trivella V; Peter J; Opie J; Louw V; Rowji P; Jacobson B; Groenewald P; Dorrington RE; Laubscher R; Bradshaw D; Moultrie H; Fairall L; Sanne I; Gail-Bekker L; Gray G; Goga A; Garrett N;
    PLoS Med; 2022 Jun; 19(6):e1004024. PubMed ID: 35727802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Kim S; Ko M; Heo Y; Lee YK; Kwon Y; Choi SK; Bahng E
    Vaccine; 2023 Aug; 41(35):5066-5071. PubMed ID: 37422379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
    Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years - United States, June 17, 2022-May 7, 2023.
    Hause AM; Marquez P; Zhang B; Moro PL; Myers TR; Bradley C; Bazel S; Panchanathan SS; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(23):621-626. PubMed ID: 37289661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.
    Hause AM; Shay DK; Klein NP; Abara WE; Baggs J; Cortese MM; Fireman B; Gee J; Glanz JM; Goddard K; Hanson KE; Hugueley B; Kenigsberg T; Kharbanda EO; Lewin B; Lewis N; Marquez P; Myers T; Naleway A; Nelson JC; Su JR; Thompson D; Olubajo B; Oster ME; Weintraub ES; Williams JTB; Yousaf AR; Zerbo O; Zhang B; Shimabukuro TT
    Pediatrics; 2022 Aug; 150(2):. PubMed ID: 35581698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.